Kexing Biopharm is an international, innovation-driven biopharma company focused on the development, manufacturing, and commercialization of recombinant proteins, antibodies drugs, and microbiome therapeutics. With a product portfolio of 22 approved drugs and a growing pipeline addressing autoimmune, oncology, viral, metabolic, and degenerative diseases, Kexing leverages its proprietary platforms (KX-FUSION, KX-BODY, K’Exosome) for breakthrough innovation.